Connect with us

Novartis’s Kymriah does not meet primary endpoint in phase III study

HBS Reporting

Novartis’s Kymriah does not meet primary endpoint in phase III study

Novartis’s Kymriah does not meet primary endpoint in phase III study

ZURICH, Aug 24 (Reuters) – Novartis ag (NOVN.S) said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not meet its primary endpoint of event-free survival in a phase III study.

The safety profile was consistent with the established safety profile of Kymriah and Novartis will complete a full evaluation of the BELINDA study data, the Swiss drugmaker said in a statement on Tuesday.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting